Novartis signs licensing deal for novel cell therapy program
This article was originally published in Clinica
Executive Summary
Novartis has struck an exclusive global licensing and research deal with small US biotech Regenerex for rights to its novel cell therapy platform. Financial terms of the partnership were not disclosed.